BNP Paribas Arbitrage SA raised its position in AveXis, Inc. (NASDAQ:AVXS) by 1,001.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,732 shares of the company’s stock after acquiring an additional 2,484 shares during the period. BNP Paribas Arbitrage SA’s holdings in AveXis were worth $224,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in AveXis in the first quarter valued at approximately $117,000. Botty Investors LLC acquired a new stake in AveXis in the second quarter valued at approximately $123,000. Virginia Retirement Systems ET AL acquired a new stake in AveXis in the first quarter valued at approximately $205,000. Seven Bridges Advisors LLC boosted its stake in AveXis by 49.4% in the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after acquiring an additional 846 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after acquiring an additional 284 shares in the last quarter. Institutional investors own 94.71% of the company’s stock.

AveXis, Inc. (NASDAQ AVXS) opened at 92.11 on Friday. The firm has a 50 day moving average of $93.16 and a 200-day moving average of $80.70. AveXis, Inc. has a 12-month low of $38.46 and a 12-month high of $99.45. The stock’s market cap is $2.94 billion.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same quarter last year, the business posted ($0.68) EPS. On average, analysts expect that AveXis, Inc. will post ($6.04) earnings per share for the current year.

Several brokerages have weighed in on AVXS. Jefferies Group LLC restated a “buy” rating and issued a $108.00 target price (up from $92.00) on shares of AveXis in a research note on Friday, August 11th. BMO Capital Markets restated a “buy” rating and issued a $123.00 target price on shares of AveXis in a research note on Friday, August 11th. Morgan Stanley restated an “overweight” rating and issued a $118.00 target price on shares of AveXis in a research note on Wednesday, August 9th. Chardan Capital set a $103.00 target price on shares of AveXis and gave the company a “buy” rating in a research note on Sunday, June 18th. Finally, Evercore ISI began coverage on shares of AveXis in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 target price for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $99.29.

In other news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $81.88, for a total value of $145,746.40. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $145,746.40. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders sold 5,340 shares of company stock valued at $474,637. Company insiders own 18.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AveXis, Inc. (AVXS) Holdings Raised by BNP Paribas Arbitrage SA” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/24/avexis-inc-avxs-holdings-raised-by-bnp-paribas-arbitrage-sa.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.